Inflation Reduction Act Benefits Medicare Patients
Drug Topics
AUGUST 26, 2022
Medicare users will see prescription drug pricing reform thanks to the Inflation Reduction Act.
Sat.Aug 20, 2022 - Fri.Aug 26, 2022
187 
Study: Myocarditis Risk Is Significantly Higher After COVID-19 Infection Vs After Vaccine
Pharmacy Times
AUGUST 24, 2022
Analysis includes nearly 43 million individuals aged 13 year and older who received at least 1 dose in England between December 1, 2020, and December 15, 2021.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Making coupons count for patients at the pharmacy counter
PhRMA
AUGUST 25, 2022
Too many patients face high out-of-pocket costs for brand medicines, even when they have insurance.
Blister material as a source of nitrosamine impurities
European Pharmaceutical Review
AUGUST 25, 2022
Following numerous recalls, the industry is striving to investigate the causes, sources and ways to mitigate carcinogenic nitrosamine impurities. In a recent paper, published in the International Journal of Pharmaceutics , researchers identified nitrocellulose blister packaging as a potential source of N -nitrosodimethylamine (NDMA) and N -nitrosodiethylamine (NDEA) impurities.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Leukemia Patients Turn to Online Pharmacies Due to Escape High Drug Prices
Drug Topics
AUGUST 25, 2022
Researchers report that half of the online pharmacies are rogue operations that may operate without a license or have other serious shortcomings.
Combination Flu, COVID-19, RSV mRNA Vaccine Could Change Immunizations Landscape
Pharmacy Times
AUGUST 23, 2022
Francesca Ceddia, MD, senior vice president of respiratory vaccines at Moderna, said the company is in early stages of development for a combined mRNA vaccine for influenza, COVID-19, and RSV.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Frazier PhRMA Scholarship awarded to four college-bound students in Philadelphia and DC
PhRMA
AUGUST 22, 2022
The Kenneth C. Frazier PhRMA Scholars Program is going strong in 2022—and we are expanding our horizons to a new city. This summer, we are thrilled to announce four new recipients: Arianna Camacho-Mendez and Axel Orellana from Washington, D.C.; and Michelle Tanujaya and Jackie Zhao, our first students from Philadelphia. Congratulations to these amazing scholars!
COVID-19: An Attack on the Brain
Drug Topics
AUGUST 25, 2022
What are the long term psychiatric and neuropsychiatric complications of COVID-19?
Pharmacists and Deprescribing in a Palliative Care Setting
Pharmacy Times
AUGUST 25, 2022
As pharmacists take on new responsibilities, researchers have been studying the effects of pharmacists on interprofessional care teams.
A List Of Medication Inspired Names For Dogs & Other Animals
IDStewardship
AUGUST 20, 2022
In this article a list of medication names for dogs and other animals is provided. Composed By: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP. Article posted 20 August 2022. Recently @HaPhanPharmD asked the twitterverse for good medication names for dogs. Many people commented, sharing some actual names of their pets (see below) or hypothetical names that would be a possible name for a dog (or pair of dogs).
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Non-viral CRISPR could overcome cell and gene therapy bottlenecks
European Pharmaceutical Review
AUGUST 26, 2022
Scientists from the Gladstone Institutes and University of California San Francisco (UCSF) say a new variation of the CRISPR-Cas9 gene editing system enables especially long DNA sequences to be introduced to precise locations in the genomes of cells with remarkably high efficiency without the need for viral vectors. “One of our goals for many years has been to put lengthy DNA instructions into a targeted site in the genome in a way that doesn’t depend on viral vectors,” commented Alex Marson, MD
Inflammatory Bowel Disease Treatment Costs Reduced with IFX biosimilar
Drug Topics
AUGUST 26, 2022
Although further studies are needed to confirm the long-term effects, recent studies have shown the infliximab biosimilar to be a safe, effective, and cost reducing treatment for inflammatory bowel diseases.
78% of Retail Pharmacists Fear Losing Patients When They Choose New Medicare Plans
Pharmacy Times
AUGUST 26, 2022
Additionally, approximately 70% who responded to the EnlivenHealth survey say that one-third or more of their revenue comes from individuals eligible for the government health insurance.
Sword’s digital musculoskeletal care approach improves mental health; study
pharmaphorum
AUGUST 26, 2022
A clinical trial has found that a digital care programme for people with musculoskeletal pain developed by Sword Health can improve their productivity at work, even if they also have mental health issues. Sword Health’s virtual musculoskeletal programme care programme pairs patients with a physical therapist they can talk with via telehealth, guiding them through exercises to address pain and other symptoms and also provides cognitive behavioural therapy (CBT) modules to help them develop
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Gilead’s Sunlenca receives EC approval to treat HIV
Pharmaceutical Technology
AUGUST 23, 2022
Gilead Sciences has obtained the European Commission (EC) marketing authorisation for Sunlenca (lenacapavir) injection and tablets to treat human immunodeficiency virus (HIV) infection. The twice-yearly treatment is indicated to be administered along with other antiretroviral(s) in adult patients with multi-drug resistant HIV infection who otherwise cannot have a suppressive anti-viral regimen.
Plaque Psoriasis Treatment Gets Even More Company
Drug Topics
AUGUST 25, 2022
Nonsteroidal topical agents and TYK2 inhibitors may join an already full armamentarium.
Foot Care Is Essential for Patients With Diabetes
Pharmacy Times
AUGUST 25, 2022
With proper knowledge, they can complete self-examinations and be adherent to clinical exams.
Merck chases Bayer/Ionis with fast track for Factor XI drug
pharmaphorum
AUGUST 24, 2022
The FDA has given a novel anticoagulant from Merck & Co a fast-track designation as a treatment for people with end-stage renal disease (ESRD) who need dialysis, firing a warning short over the bows of a rival programme in development at Ionis and Bayer. The anticoagulant – codenamed MK-2060 – is a monoclonal antibody designed to inhibit Factor XI and is currently in a phase 2b trial in ESRD patients on dialysis, who often need to be treated with anticoagulants to prevent blood clots.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Oncolytic viruses: past and present
European Pharmaceutical Review
AUGUST 25, 2022
IN 2022, treating glioblastoma (GBM) remains an uphill battle. Current therapeutic options show limited success and neuro-oncology teams often struggle to balance their benefits with a patient’s quality of life. Cutting-edge strategies, however, are now revisiting the use of oncolytic viruses – viruses that selectively infect and kill cancer cells – which may broaden and advance the therapeutic landscape.
COVID-19 Incubation Period Varies by SARS-CoV-2 Strain
Drug Topics
AUGUST 25, 2022
With the evolution of different COVID-19 variants, finding the mean incubation period has become more complex.
Trial Results Suggest Metformin Is Effective at Reducing Odds of Serious COVID-19 Outcomes
Pharmacy Times
AUGUST 22, 2022
University of Minnesota Medical School Analysis shows comparison with fluvoxamine and ivermectin in a double-blinded, placebo-controlled, randomized study.
Roctavian okay sets up another gene therapy test for Europe
pharmaphorum
AUGUST 26, 2022
BioMarin Pharma has its landmark first approval for Roctavian – the first for a haemophilia gene therapy – and will now have to see if that can convert that into a viable business in Europe. The US biotech claimed conditional marketing approval from the European Commission for Roctavian (valoctocogene roxaparvovec) as a treatment for adults with severe haemophilia A, who don’t have a history of developing the antibodies that inhibit the activity of blood-clotting protein Factor VIII.
Outsourcing strategists thinking farther ahead than ever: CPHI
Outsourcing Pharma
AUGUST 23, 2022
The groupâs latest report glimpses inside the minds of pharma leaders, who are looking at a productâs full life-cycle development at the preclinical stage.
Patents, pandemics and pricing: a peek at the top drug from every big pharma
PharmaVoice
AUGUST 22, 2022
A look at how the biggest pharma companies in the world and their top-selling drugs fared in the first half of the year.
Expert: Mark Cuban’s Pharmacy Has Shown ‘There’s No Silver Bullet’ to Disrupt the Pharmacy Value Chain
Pharmacy Times
AUGUST 26, 2022
Yoona Kim, PharmD, PhD, co-founder and CEO of Arine, discusses some of the key takeaways from the launch of Mark Cuban's pharmacy Mark Cuban Cost Plus Drug Co.
Takeda gets first approval for its dengue vaccine
pharmaphorum
AUGUST 23, 2022
Japan’s Takeda has secured its first regulatory approval – in Indonesia – for its dengue fever vaccine TAK-003, which has been tipped as a potential blockbuster product. Indonesia’s National Agency for Drug and Food Control (BPOM) has approved the vaccine as Qdenga to protect against the virus in people aged six to 45, on the back of data showing that it can cut dengue-related hospitalisations by 84%, with 61% protective efficacy against symptomatic illness seen up to three years aft
EC grants approval for BioMarin’s gene therapy to treat Hemophilia A
Pharmaceutical Technology
AUGUST 25, 2022
The European Commission (EC) has granted conditional marketing authorisation (CMA) for BioMarin Pharmaceutical ’s gene therapy, Roctavian (valoctocogene roxaparvovec), to treat adults with severe haemophilia A (congenital Factor VIII deficiency). The treatment is indicated for patients with no history of Factor VIII inhibitors and any detectable antibodies to adeno-associated virus serotype 5 (AAV5).
The story behind the PharmaVoice 100
PharmaVoice
AUGUST 23, 2022
Taren Grom, our editor-in-chief emeritus, explains how the coveted PharmaVoice 100 awards got its start and what makes it stand out in the industry.
COVID-19 Vaccine Booster Dose Reduces Infection, Hospitalization, Death from Virus in Long-Term Care Facilities
Pharmacy Times
AUGUST 25, 2022
During the surge caused by the Delta variant, a third dose of the Pfizer-BioNTech COVID-19 vaccine reduced infections and COVID-19-related hospitalizations and deaths among patients in long term care facilities.
To build diversity into clinical trials, collaborate at the community level
pharmaphorum
AUGUST 24, 2022
Diversity in clinical trials is a “scientific imperative”, but how can industry bridge the gap between “why” and “how”? Removing barriers to clinical trial participation for underserved groups is an essential part of addressing health inequalities. Getting there, however, is easier said than done. The Food and Drug Administration’s (FDA) draft guidance, Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Subgroups in Clinical Trials , recommends sponsors
Environmental Monitoring In-Depth Focus 2022
European Pharmaceutical Review
AUGUST 24, 2022
A strategic approach to optimisations of testing bacterial endotoxins. Given industry’s recent focus on the sustainability of bacterial endotoxin testing (BET), here, AstraZeneca colleagues Miriam Guest, Karen Capper, Dennis Wong and Phil Duncanson share how they worked to establish a short-, mid- and long-term strategy to optimise BET across the global enterprise.
With market success at stake, can tech help solve the diversity problem in clinical trials?
PharmaVoice
AUGUST 24, 2022
Diversity in clinical trials isn’t only important for the health of the overall patient population — it can save millions in lost profits.
Daily Medication Pearl: Dextromethorphan and Bupropion (Auvelity)
Pharmacy Times
AUGUST 24, 2022
Auvelity is a combination of dextromethorphan and bupropion indicated for the treatment of major depressive disorder in adults.
Let's personalize your content